Cite
HARVARD Citation
Wolf, J. et al. (n.d.). LBA52Results of the GEOMETRY mono-1 phase II study for evaluation of the MET inhibitor capmatinib (INC280) in patients (pts) with METΔex14 mutated advanced non-small cell lung cancer (NSCLC). Annals of oncology. p. . [Online].